Standard BioTools Files 8-K on Financials

Ticker: LAB · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1162194

Standard Biotools Inc. 8-K Filing Summary
FieldDetail
CompanyStandard Biotools Inc. (LAB)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K

TL;DR

Standard BioTools dropped an 8-K on Jan 13th covering financials. Check it for deets.

AI Summary

Standard BioTools Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company, formerly known as Fluidigm Corp, is incorporated in Delaware and headquartered in South San Francisco, California.

Why It Matters

This 8-K filing provides crucial updates on Standard BioTools' financial performance and operational status, which are important for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) and does not inherently indicate new risks.

Key Players & Entities

  • Standard BioTools Inc. (company) — Registrant
  • January 13, 2025 (date) — Date of report
  • Delaware (jurisdiction) — State of Incorporation
  • South San Francisco, California (location) — Principal Executive Offices
  • Fluidigm Corp (company) — Former Company Name

FAQ

What specific financial information is being reported in this 8-K?

The 8-K filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the header information.

When was this 8-K report filed?

The report was filed on January 13, 2025.

What was Standard BioTools Inc. formerly known as?

Standard BioTools Inc. was formerly known as Fluidigm Corp.

Where are Standard BioTools Inc.'s principal executive offices located?

The principal executive offices are located at 2 Tower Place, Suite 2000, South San Francisco, California 94080.

What is the Central Index Key (CIK) for Standard BioTools Inc.?

The Central Index Key for Standard BioTools Inc. is 0001162194.

Filing Stats: 713 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-13 07:08:08

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share LAB Nasdaq Global Select Ma

Filing Documents

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Standard BioTools Inc. (the "Company") issued a press release and updated its investor presentation, as described further below, which included information with respect to certain preliminary financial results of the Company for the three months and fiscal year ended December 31, 2024. The press release and investor presentation are attached hereto as Exhibits 99.1 and 99.2, respectively, and incorporated herein by reference. The Company's preliminary financial results are unaudited and based on current expectations and may be adjusted as a result of, among other things, completion of annual audit procedures. This financial information does not represent a comprehensive statement of the Company's financial results for the three months or fiscal year ended December 31, 2024 and remains subject to the completion of financial closing procedures and internal reviews.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On January 13, 2025, the Company updated its investor presentation, which the Company expects to use in connection with general corporate presentations and will be made available on the Company's website or distributed by the Company in hardcopy or electronic form. The investor presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference. The investor presentation is current as of January 13, 2025, and the Company disclaims any obligation to update the investor presentation after such date.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Standard BioTools Inc., dated January 13, 2025. 99.2 Investor Presentation of Standard BioTools Inc., dated January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 STANDARD BIOTOOLS INC. By: /s/ Alex Kim Name: Alex Kim Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.